Efficacy and tolerability of first line ketogenic diet versus high dose adrenocorticotrophic hormone therapy and infantile spasm syndrome: An open label randomised controlled trial

被引：0

作者：

Mahesan, A. ^{[1
]}

Sondhi, V. ^{[2
]}

Agarwala, A. ^{[3
]}

Gupta, K. L. ^{[3
]}

Kamila, G. ^{[1
]}

Jauhari, P. ^{[1
]}

Chakrabarty, B. ^{[1
]}

Pandey, R. M. ^{[4
]}

Gulati, S. ^{[1
]}

机构：

[1] All India Inst Med Sci, Child Neurol Div, Pediat, New Delhi, India

[2] AFMC, Pediat, Pune, Maharashtra, India

[3] All India Inst Med Sci, Senior Dietician, Pediat, New Delhi, India

[4] All India Inst Med Sci, Biostatist, New Delhi, India

来源：

EPILEPSIA | 2024年 / 65卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

457

引用

页码：381 / 381

页数：1

共 50 条

[21] First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial
Jongsma, Maria M. E.
Aardoom, Martine A.
Cozijnsen, Martinus A.
van Pieterson, Merel
de Meij, Tim
Groeneweg, Michael
Norbruis, Obbe F.
Wolters, Victorien M.
van Wering, Herbert M.
Hojsak, Iva
Kolho, Kaija-Leena
Hummel, Thalia
Stapelbroek, Janneke
van der Feen, Cathelijne
van Rheenen, Patrick F.
van Wijk, Michiel P.
Teklenburg-Roord, Sarah T. A.
Schreurs, Marco W. J.
Rizopoulos, Dimitris
Doukas, Michail
Escher, Johanna C.
Samsom, Janneke N.
de Ridder, Lissy
GUT, 2022, 71 (01) : 34 - 42
[22] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial (vol 11, pg 29, 2010)
Rajkumar, S., V
Jacobus, S.
Callander, N. S.
LANCET ONCOLOGY, 2010, 11 (01): : 14 - 14
[23] Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Suen, Christopher Li Wai
Choy, Matthew
Con, Danny
Boyd, Kristy
Pena, Raquel
Burrell, Kathryn
Rosella, Ourania
Proud, David
Brouwer, Richard
Gorelik, Alexandra
Liew, Danny
Connell, William R.
Wright, Emily K.
Taylor, Kirstin M.
Pudipeddi, Aviv
Sawers, Michelle
Christensen, Britt
Ng, Watson
Begun, Jakob
Radford-Smith, Graham
Garg, Mayur
Martin, Neal
Van Langenberg, Daniel
Ding, John Nik
Beswick, Lauren
Leong, Rupert
Sparrow, Miles P.
De Cruz, Peter
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 240 - 240
[24] Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Choy, Matthew C.
Suen, Christopher F. D. Li Wai
Con, Danny
Boyd, Kristy
Pena, Raquel
Burrell, Kathryn
Rosella, Ourania
Proud, David
Brouwer, Richard
Gorelik, Alexandra
Liew, Danny
Connell, William R.
Wright, Emily K.
Taylor, Kirstin M.
Pudipeddi, Aviv
Sawers, Michelle
Christensen, Britt
Ng, Watson
Begun, Jakob
Radford-Smith, Graham
Garg, Mayur
Martin, Neal
Langenberg, Daniel R. van
Ding, Nik S.
Beswick, Lauren
Leong, Rupert W.
Sparrow, Miles P.
De Cruz, Peter
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (11): : 981 - 996
[25] All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial
Huang, Qiu-Sha
Liu, Yi
Wang, Jing-Bo
Peng, Jun
Hou, Ming
Liu, Hui
Feng, Ru
Wang, Jing-Wen
Xu, Lan-Ping
Wang, Yang
Huang, Xiao-Jun
Zhang, Xiao-Hui
LANCET HAEMATOLOGY, 2021, 8 (10): : E688 - E699
[26] Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET 020)
An, Zhuo-Yu
Wu, Ye-Jun
He, Yun
Zhu, Xiao-Lu
Shi, Hong-Xia
Wang, Chen-Cong
Jiang, Hao
Lu, Jin
Jiang, Qian
Huang, Qiu-Sha
Fu, Hai-Xia
Wang, Feng-Rong
Mo, Xiao-Dong
Wang, Yu
Zhao, Xiang-Yu
Zhang, Yuan-Yuan
Han, Wei
Chen, Huan
Chen, Yao
Yan, Chen-Hua
Wang, Jing-Zhi
Han, Ting-Ting
Chen, Yu-Hong
Cheng, Yi-Fei
Chang, Ying-Jun
Xu, Lan-Ping
Liu, Kai-Yan
Huang, Xiao-Jun
Zhang, Xiaohui
BLOOD, 2021, 138
[27] Clinical Efficacy and Safety of Injectable Levetiracetam Versus Phenytoin as Second-Line Therapy in the Management of Generalized Convulsive Status Epilepticus in Children: An Open-Label Randomized Controlled Trial
Noureen, Nuzhat
Khan, Saadia
Khursheed, Asim
Iqbal, Imran
Maryam, Moallah
Sharib, Syed Muhammad
Maheshwary, Neeta
JOURNAL OF CLINICAL NEUROLOGY, 2019, 15 (04): : 468 - 472
[28] Efficacy and safety of high dose twice-daily thoracic radiotherapy versus standard dose for limited stage small-cell lung cancer: A multicentre, open-label randomised, phase 3 trial
Yu, Jiayi
Jiang, Leilei
Zhao, Lina
Wang, Xiaomin
Yang, Xue
Yang, Dan
Zhuo, Minglei
Chen, Hanxiao
Zhao, Yidian
Zhou, Fang
Li, Quanfu
Zhu, Zhengfei
Chu, Li
Ma, Zhanshu
Wang, Qifeng
Qu, Yanli
Yu, Huiming
Yu, Rong
Zhao, Jun
Shi, Anhui
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial
Romera, Alvaro
Peredpaya, Sergiy
Shparyk, Yaroslav
Bondarenko, Igor
Bariani, Giovanni Mendonca
Abdalla, Kathia Cristina
Roca, Enrique
Franke, Fabio
Cruz, Felipe Melo
Ramesh, Anita
Ostwal, Vikas
Shah, Pradeep
Rahuman, Sajeed Abdul
Paravisini, Alexandra
Huerga, Camino
Garcia, Ana Del Campo
Millan, Susana
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (12): : 845 - 855
[30] Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho
Amstutz, Alain
Nsakala, Bienvenu Lengo
Vanobberghen, Fiona
Muhairwe, Josephine
Glass, Tracy Renee
Namane, Tilo
Mpholo, Tian
Battegay, Manuel
Klimkait, Thomas
Labhardt, Niklaus Daniel
PLOS MEDICINE, 2020, 17 (09)

← 1 2 3 4 5 →